Literature DB >> 33729032

Rapid Point-of-Care Test for Determination of C-Peptide Levels.

Paturi V Rao1, Eric Bean1, Dhanalakshmi Nair-Schaef1, Siting Chen2, Steven C Kazmierczak3, Charles T Roberts1, Srinivasa R Nagalla1.   

Abstract

C-peptide is co-secreted with insulin and is not subject to hepatic clearance and thus reflects functional β-cell mass. Assessment of C-peptide levels can identify individuals at risk for or with type 1 diabetes with residual β-cell function in whom β cell-sparing interventions can be evaluated, and can aid in distinguishing type 2 diabetes from Latent Autoimmune Diabetes in Adults and late-onset type 1 diabetes. To facilitate C-peptide testing, we describe a quantitative point-of-care C-peptide test. C-peptide levels as low as 0.2 ng/ml were measurable in a fingerstick sample, and the test was accurate over a range of 0.17 to 12.0 ng/ml. This test exhibited a correlation of r = 0.98 with a high-sensitivity commercial ELISA assay and a correlation of r = 0.90 between matched serum and fingerstick samples.

Entities:  

Keywords:  C-peptide; LADA; MODY; diabetes; point-of-care

Mesh:

Substances:

Year:  2021        PMID: 33729032      PMCID: PMC9264426          DOI: 10.1177/1932296821995557

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  44 in total

Review 1.  Type 1 diabetes: etiology, immunology, and therapeutic strategies.

Authors:  Tom L van Belle; Ken T Coppieters; Matthias G von Herrath
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

2.  C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.

Authors:  Magdalena M Bogun; Brian N Bundy; Robin S Goland; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2020-05-26       Impact factor: 19.112

3.  Decline Pattern of Beta-cell Function in Adult-onset Latent Autoimmune Diabetes: an 8-year Prospective Study.

Authors:  Xia Li; Yan Chen; Yuting Xie; Yufei Xiang; Xiang Yan; Gan Huang; Zhiguang Zhou
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

4.  Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.

Authors:  Beverley M Shields; Maggie Shepherd; Michelle Hudson; Timothy J McDonald; Kevin Colclough; Jaime Peters; Bridget Knight; Chris Hyde; Sian Ellard; Ewan R Pearson; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2017-08       Impact factor: 19.112

Review 5.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

6.  The Impact of Precision Medicine in Diabetes: A Multidimensional Perspective.

Authors:  Stephen S Rich; William T Cefalu
Journal:  Diabetes Care       Date:  2016-11       Impact factor: 19.112

7.  Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes.

Authors:  Nicholas J Thomas; Anita L Lynam; Anita V Hill; Michael N Weedon; Beverley M Shields; Richard A Oram; Timothy J McDonald; Andrew T Hattersley; Angus G Jones
Journal:  Diabetologia       Date:  2019-04-10       Impact factor: 10.122

8.  Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.

Authors:  Annelie Carlsson; Maggie Shepherd; Sian Ellard; Michael Weedon; Åke Lernmark; Gun Forsander; Kevin Colclough; Qefsere Brahimi; Camilla Valtonen-Andre; Sten A Ivarsson; Helena Elding Larsson; Ulf Samuelsson; Eva Örtqvist; Leif Groop; Johnny Ludvigsson; Claude Marcus; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2019-11-08       Impact factor: 19.112

9.  Variation of C peptide decay rate in diabetic patients with positive glutamic acid decarboxylase antibody: better discrimination with initial fasting C peptide.

Authors:  Xia Li; Gan Huang; Jian Lin; Lin Yang; Zhiguang Zhou
Journal:  BMC Endocr Disord       Date:  2013-03-01       Impact factor: 2.763

10.  Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Della Matheson; Jay S Skyler
Journal:  Diabetes Care       Date:  2008-07-23       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.